ASA’s new section for Medical Devices and Diagnostics

 

I am not sure everyone is aware, but I wanted to introduce everyone to SIGMEDD (statistics interest group for medical devices and diagnostics).  It is an interest group of the American Statistical Association (ASA), and the group is composed of statisticians who are interested in applying and developing statistical method for evaluating medical and diagnostic devices.  I am the current Chair-Elect for 2012, and will be the Chair for 2013.  Our website is at: http://www.amstat.org/sections/sigmedd/

We are looking to become a full section within the ASA, instead of a special interest group.  In order to apply we need a minimum of 100 signatures from ASA members–and we'd like to get many more to show the interest in devices and diagnostics (so ASA can't say no!).  If you are an ASA member, and support SIGMEDD having its own section of the ASA, you should sign the following petition and email to the contacts listed: http://www.amstat.org/sections/sigmedd/Announcement/SMDD%20petition%20form.pdf

 

More Recent News

February 2024 QUOTES Webinar

Berry Consultants will be hosting a webinar on the optimization of a clinical trial design by estimating its impact on the expected net present value of a drug development program using the software QUOTES (Quantification and Optimization of Trial Expectations Simulator).

Blog: Precision Promise Adaptive Platform Trial update

Blog by: Kert Viele News from the Precision Promise platform trial. https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-announces-completion-pamrevlumab-arm-precision-promise Precision Promise is an adaptive platform trial investigating potential therapies for pancreatic cancer,

January 2024 FACTS Webinar

The Berry Consultants software team will be hosting its January FACTS webinar next Friday, January 19th at 11am EST to present the development plans for adding an ordinal endpoint option to the trial simulator.

Blog: Comments on the draft FDA master protocol guidance

Blog by: Kert Viele The FDA draft master protocol guidance is out https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development Comments are due by February 22. Here are some preliminary thoughts and